Our focus is on the development of compounds for combination use in high impact carcinomas including glioblastoma, ovarian, breast, and pancreatic cancers. We have completed studies of our lead compound, 9-ING-41, in preclinical patient-derived xenograft models of cancers, including both drug sensitive and drug resistant glioblastoma, results of which are quite compelling, including complete and durable regressions of disease without recurrences, and significant increases in overall survival. Our compounds have been well tolerated and have demonstrated a favorable pharmacokinetic profile.
In addition, we are advancing research for the development of our compounds for the treatment of inflammation leading to fibrosis and neurodegeneration, where results of early studies in animal models are promising.
Currently, the Company has pharmacology and toxicology studies underway to optimize the formulation and dosing regimen of our lead drug candidate prior to human testing. These studies will be used to support a human trial planned for initiation in early 2018.